medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Número 2

<< Anterior Siguiente >>

Rev Mex Neuroci 2019; 20 (2)


Clinical guideline: antiepileptic drugs of choice for epileptic syndromes and epilepsies in pediatric patients

Reséndiz-Aparicio JC, Padilla-Huicab JM, Martínez-Juárez IE, Hernández-Martínez G, López-Correa E, Vázquez-Juárez B, Huerta-Albarrán R, Rivera-Acuña C

Idioma: Ingles.
Referencias bibliográficas: 52
Paginas: 89-96
Archivo PDF: 172.62 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB. Pharmacotherapy for neonatal seizures: current knowledge and future perspectives. Drugs. 2016;76:647-61.

  2. Sankaraneni R, Lachhwani D. Antiepileptic drugs a review. Pediatr Ann. 2015;44:e36-42.

  3. Pellock JM, Arzimanoglou A, D’Cruz O, et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: the case for disease similarity. Epilepsia. 2017;58:1686-96.

  4. Yozawitz E, Stacey A, Pressler RM. Pharmacotherapy for seizures in neonates with hypoxic ischemic encephalopathy. Paediatr Drugs. 2017; 19:553-67.

  5. Linder C, Wide K, Walander M, et al. Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling. Clin Biochem. 2017;50:418-24.

  6. Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016; 18:367-83.

  7. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82.

  8. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512-21.

  9. Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology. 2017; 89:893-9.

  10. Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57:2019-30.

  11. Yamamoto H, Okumura A, Fukuda M. Epilepsies and epileptic syndromes starting in the neonatal period. Brain Dev. 2011;33:213-20.

  12. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American academy of neurology and the practice committee of the child neurology society. Neurology. 2012; 78:1974-80.

  13. Hancock EC, Osborne JP, Edwards SW. Treatment of Infantile Spasms. Copyright © 2014 the Cochrane Collaboration. Hoboken: Publicado Por John Wiley and Sons, Ltd.; 2014.

  14. Tournay AE. DynaMed Plus: patients with Lennox-Gastaut Síndrome. Spain: Marzo; 2018.

  15. Epilepsies: Diagnosis and Management. Clinical Guideline Publicada: 11 Enero; 2012. http://www.nice.org.uk/guidance/cg137.

  16. Lemmon ME, Kossoff EH. New treatment options for lennox-gastaut syndrome. Curr Treat Options Neurol. 2013;15:519-28.

  17. Hancock EC, Cross H. Treatment of Lennox-Gastaut syndrome. Copyright © 2013 the Cochrane Collaboration. Hoboken: Publicado Por John Wiley and Sons, Ltd.; 2013.

  18. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the lennox-gastaut syndrome. Lamictal lennox- gastaut study group. N Engl J Med. 1997;337:1807-12.

  19. Kossoff EH, Shields WD. Nonpharmacologic care for patients with lennox- gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia. 2014;55 Suppl 4:29-33.

  20. Lancman G, Virk M, Shao H, et al. Vagus nerve stimulation vs. Corpus callosotomy in the treatment of lennox-gastaut syndrome: a meta-analysis. Seizure. 2013;22:3-8.

  21. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391:1085-96.

  22. Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current israeli experience. Seizure. 2016;35:41-4.

  23. Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the children’s hospital of Philadelphia. Epilepsia. 2007;48:1703-7.

  24. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52:988-93.

  25. von Stülpnagel C, Coppola G, Striano P, et al. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Paediatr Neurol. 2012;16:459-63.

  26. Mizrahi EM, Watanabe K, Symptomatic neonatal seizures. In: Roger J, Bureau M, Dravet CH, editors Epileptic Syndromes in Infancy, Childhood and Adolescencie. 3rd ed. London: John Libbey; 2002.

  27. Weir E, Gibbs J, Appleton R. Panayiotopoulos syndrome and benign partial epilepsy with centro-temporal spikes: a comparative incidence study. Seizure. 2018;57:66-9.

  28. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-120.

  29. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-63.

  30. Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics. Epilepsia. 2015;56:1185-97.

  31. Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev. 2018; 7:CD009258.

  32. Nevitt SJ, Marson AG, Weston J, Smith CT. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2017;2:CD001911.

  33. Nevitt SJ, Smith CT, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018;6:CD001031.

  34. Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr. 2013; 50:1033-40.

  35. Sánchez-Álvarez JC, Ramos-Lizana J, Machado-Casas IS, et al. Combined treatment with antiepileptic drugs. Andalusian epilepsy guide 2015. Rev Neurol. 2015;60:365-79.

  36. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000-15.

  37. Smith CT, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. 2007;8:34.

  38. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-8.

  39. Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55:1088-98.

  40. Lang N, Lange M, Schmitt FC, et al. Intravenous lacosamide in clinical practice-results from an independent registry. Seizure. 2016;39:5-9.

  41. Maguire M, Marson AG, Ramaratnam S. Epilepsy (partial). BMJ Clin Evid. 2011;2011:1214.

  42. Smith CT, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003; 1:CD001904.

  43. Nolan SJ, Smith CT, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;1:CD002217.

  44. Nolan SJ, Marson AG, Pulman J, Smith CT. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;8:CD001769.

  45. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-75.

  46. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2006; 1:CD001031.

  47. Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs. 2013;27:273-86.

  48. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; 4:CD006453.

  49. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol. 2008;23:515-9.

  50. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian study group for childhood epilepsy. Epilepsia. 1998;39:952-9.

  51. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian study group for childhood epilepsy. Epilepsy Res. 1999; 33:133-43.

  52. Rosenow F, Schade-Brittinger C, Burchardi N, et al. The laLiMo trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83:1093-8.




2020     |     www.medigraphic.com